Senzagen started trading on Nasdaq First North on 21 September 2017.
SenzaGen provides in vitro testing for the cosmetic, chemical and pharmaceutical industries, which obviates the need for animal testing.
Ålandsbanken Funds Ltd is among the major investors.
Vator Securities is the financial advisor and Baker McKenzie is legal advisor to SenzaGen. The lawyers mainly involved in the IPO from Baker McKenzie were Joakim Falkner, Stefan Balazs, Ian Gulam and Per Blom.